Probatebeta
Target

DRD3

Dopamine receptor D3

As of the edition of 20 October 2026, DRD3 (dopamine receptor D3, UniProt P35462) has 39 drugs tested at it and 52 companies on the list, 8 on route A and 14 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P35462
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
13
Disease areas
Nervous system; Mental health; Nutrition and metabolism; Cancer; Chemically induced; Heart and blood vessels; Hormones; Inherited and neonatal
Registered trials of its drugs
1,008

Drugs at this target

StatusCount
Marketed23
Active2
Went quiet4
Stopped7
Withdrawn from market2
Status not established1
Total39
DrugStatusFurthest phaseUS protection
OlanzapineMarketedPhase 4none listed
LevodopaMarketedPhase 4none listed
PramipexoleMarketedPhase 4none listed
RotigotineMarketedPhase 4none listed
HaloperidolMarketedPhase 4none listed
AmisulprideMarketedPhase 4none listed
CariprazineMarketedPhase 4Ends 2029
RopiniroleMarketedPhase 4none listed
ApomorphineMarketedPhase 4none listed
BromocriptineMarketedPhase 4none listed
LoxapineMarketedPhase 4none listed
DexpramipexoleStoppedPhase 3none listed

12 of 39 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A8
Route B14
Engaged14
Undetermined16
Total on the list52
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
Newron PharmaceuticalsRoute A
Eli LillyRoute B

The other 49 companies at DRD3

In the product

52 companies in all; 49 are not named here, and no score is.

See the 52 companies at DRD3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at DRD3

Other targets in nervous system

Companies holding approvals at DRD3